Hyasynth Biologicals Inc.

Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI) released its results for the fourth quarter and year ended August 31, 2022, revealing net revenue in FY 2022 increased 84% to $145.8 million from $79.2 million in the previous year primarily due to an increase in recreational and international...

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has invested an additional $2.5 million in a private biotechnology company Hyasynth Biologicals Inc. It’s the second tranche of financing under the $10 million debenture purchase deal between Organigram Inc. – a subsidiary of...